ContraVir

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ContraVir and buy or sell other stocks, ETFs, and their options commission-free!

About CTRV

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. 

CEO
Gary S. Stetz, MBA
CEOGary S. Stetz, MBA
Employees
Employees
Headquarters
Morristown, New Jersey
HeadquartersMorristown, New Jersey
Founded
2013
Founded2013
Employees
Employees

CTRV Key Statistics

Market cap
639.10K
Market cap639.10K
Price-Earnings ratio
-0.02
Price-Earnings ratio-0.02
Dividend yield
Dividend yield
Average volume
6.41K
Average volume6.41K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.7464
52 Week high$0.7464
52 Week low
$0.033
52 Week low$0.033

Stock Snapshot

With a market cap of 639.1K, ContraVir(CTRV) trades at $3.33. The stock has a price-to-earnings ratio of -0.02.

On 2026-04-04, ContraVir(CTRV) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for ContraVir(CTRV) stock has reached 0, versus its average volume of 6.41K.

Over the past 52 weeks, ContraVir(CTRV) stock has traded between a high of $0.75 and a low of $0.03.

Over the past 52 weeks, ContraVir(CTRV) stock has traded between a high of $0.75 and a low of $0.03.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.